The report provides a detailed analysis essential for establishing a brivaracetam production plant. It encompasses all critical aspects necessary for brivaracetam production, including the cost of brivaracetam production, brivaracetam plant cost, brivaracetam production costs, and the overall brivaracetam production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a brivaracetam production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Brivaracetam is an antiepileptic medicine that is mainly used in the treatment of seizure disorders. It is primarily prescribed for the treatment of partial-onset seizures in patients with epilepsy, either alone or in combination with other anti-seizure medications. It works by acting on specific proteins in the brain known as synaptic vesicle protein 2A, to help reduce abnormal electrical activity that leads to seizures. Its main application is in reducing the frequency and severity of seizures in patients with epilepsy. It is available in tablet, oral solution, and injectable forms, which makes it suitable for both regular and hospital-based treatment. It serves as part of a long-term treatment plan focused on improving seizure control and supporting better daily functioning in individuals living with epilepsy. Moreover, it is also used in managing other neurological conditions associated with seizures and abnormal brain activity.
The market for brivaracetam is driven by its application as an anticonvulsant medication to treat partial-onset seizures in epilepsy patients, which significantly promotes its demand in the pharmaceutical industry. Its application in combination with drugs like levetiracetam to manage focal seizures in adults and children aged 1 month or older further boosts its demand in the pharmaceutical and healthcare industries. Its demand as an anti-seizure medicine in long term treatment of patients with epilepsy to significantly reduce seizure frequency by 50% or more also drives its market expansion. The growing awareness about advanced seizure management options and increasing use as an add-on therapy with other seizure drugs also promotes its demand in the neurology drug market. Moreover, improvements in drug formulation, reliable supply chains, patent status, and efficient distribution networks also play a significant role in shaping industrial brivaracetam procurement across the world. Additionally, procurement processes are also influenced by factors such as the cost and availability of active pharmaceutical ingredients, regulatory approvals, and strict quality compliance requirements.
Raw Material for Brivaracetam Production
According to the brivaracetam production plant project report, the major raw materials for brivaracetam production include dimethyl n-propylmalonate, tert-butyl 2-bromoacetate, Protease C (from Bacillus subtilis), hydrobromic acid, and (S)-2-aminobutanamide.
Production Process of Brivaracetam
The extensive brivaracetam production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of brivaracetam begins with the alkylation of commercial dimethyl n-propylmalonate using tert-butyl 2-bromoacetate, followed by Krapcho decarboxylation to form a racemic succinate intermediate. Then, the process of enzymatic resolution using a protease from Bacillus subtilis, which selectively converts one enantiomer into the corresponding acid, allows separation and isolation of the desired chiral acid. Further, the resolved acid is activated and reduced to the corresponding alcohol, which undergoes cyclisation under acidic conditions to form a lactone intermediate. Then, this lactone intermediate undergoes treatment with hydrobromic acid to form bromoester, which is further coupled with (S)-2-aminobutanamide in the presence of a catalyst. This step introduces the required side chain and promotes lactam formation. The final product is isolated through filtration and recrystallisation to obtain brivaracetam with high enantiomeric purity.
The compound decomposes on heating and does not exhibit a defined atmospheric boiling point.